Try our beta test site
120 studies found for:    "CINJ" OR "Cancer Intitute of New Jersey" | Open Studies | United States, New Jersey
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
61 Recruiting Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Brenner Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Behavioral: Behavioral Dietary Intervention;   Behavioral: Compliance Monitoring;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Number Enrolled: 1070
Gender: Female
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT00719303
62 Recruiting Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer
Conditions: Stage IB Non-Small Cell Lung Carcinoma;   Stage II Non-Small Cell Lung Cancer;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 714
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02595944
63 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive Side Effects of Cancer Therapy;   Psychological Impact of Cancer;   Radiation Toxicity;   Sexual Dysfunction and Infertility;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 780
Gender: Female
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01414608
64 Recruiting Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Elotuzumab;   Drug: Pomalidomide;   Drug: Dexamethasone
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 406
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02726581
65 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 756
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01863550
66 Recruiting A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid
Intervention: Drug: Lenalidomide
Study Type: Interventional
Phase: Phase 2
Funder Type: Industry
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 43
Gender: All
Age: 1 Year to 18 Years   (Child, Adult)
NCT Number: NCT02538965
67 Recruiting High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Conditions: Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Melanoma of the Skin;   Recurrent Non-Cutaneous Melanoma;   Stage III Mucosal Melanoma of the Head and Neck;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma;   Stage IVA Mucosal Melanoma of the Head and Neck;   Stage IVB Mucosal Melanoma of the Head and Neck;   Stage IVC Mucosal Melanoma of the Head and Neck
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Participant, Investigator;   Primary Purpose: Treatment
Number Enrolled: 1240
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02506153
68 Recruiting Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
Condition: Anemia, Sickle Cell
Interventions: Drug: Rivipansel;   Other: Placebo
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Participant, Care Provider, Investigator, Outcomes Assessor;   Primary Purpose: Treatment
Number Enrolled: 350
Gender: All
Age: 6 Years and older   (Child, Adult, Senior)
NCT Number: NCT02187003
69 Recruiting A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Biological: ALT-803
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry / NIH
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 20
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01946789
70 Recruiting Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Conditions: Myelodysplastic Syndrome;   MDS;   Refractory Anemia With Excess Blasts;   RAEB
Interventions: Drug: rigosertib;   Drug: Any approved or standard-of-care therapy;   Drug: best supportive care (BSC)
Study Type: Interventional
Phase: Phase 3
Funder Type: Industry
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 225
Gender: All
Age: 18 Years to 81 Years   (Adult, Senior)
NCT Number: NCT02562443
71 Recruiting S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: TAK-700;   Drug: Bicalutamide
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / Industry / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 1304
Gender: Male
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01809691
72 Recruiting Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
Conditions: Clear Cell Renal Cell Carcinoma;   Renal Pelvis Urothelial Carcinoma;   Stage III Bladder Adenocarcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage III Renal Cell Cancer;   Stage III Renal Pelvis Carcinoma;   Stage III Ureter Cancer;   Stage III Urethral Cancer;   Stage IV Bladder Adenocarcinoma;   Stage IV Bladder Squamous Cell Carcinoma;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Renal Cell Cancer;   Stage IV Renal Pelvis Carcinoma;   Stage IV Ureter Cancer;   Stage IV Urethral Cancer;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Study Type: Interventional
Phase: Phase 1
Funder Type: NIH
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 113
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02496208
73 Recruiting Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer.
Intervention: Drug: ceritinib
Study Type: Interventional
Phase: Phase 1
Funder Type: Industry
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 300
Gender: All
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT02299505
74 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
Study Type: Interventional
Phase: Phase 3
Funder Type: Other / NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Number Enrolled: 1636
Gender: Female
Age: 18 Years and older   (Adult, Senior)
NCT Number: NCT01872975
75 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 5437
Gender: All
Age: 1 Year to 30 Years   (Child, Adult)
NCT Number: NCT02883049
76 Recruiting Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Leukemia Cutis;   Myeloid Sarcoma;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
Interventions: Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 1750
Gender: All
Age: up to 29 Years   (Child, Adult)
NCT Number: NCT01371981
77 Recruiting Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Number Enrolled: 14250
Gender: All
Age: up to 30 Years   (Child, Adult)
NCT Number: NCT01142427
78 Recruiting Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Conditions: PRETEXT Stage 1 Hepatoblastoma;   PRETEXT Stage 2 Hepatoblastoma;   PRETEXT Stage 3 Hepatoblastoma;   PRETEXT Stage 4 Hepatoblastoma
Interventions: Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 253
Gender: All
Age: up to 21 Years   (Child, Adult)
NCT Number: NCT00980460
79 Recruiting Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Conditions: Acute Lymphoblastic Leukemia;   Brain Neoplasm;   Hodgkin Lymphoma;   Rhabdomyosarcoma
Interventions: Procedure: Assessment of Therapy Complications;   Other: Questionnaire Administration
Study Type: Observational
Phase:
Funder Type: Other / NIH
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Number Enrolled: 4485
Gender: All
Age: Child, Adult, Senior
NCT Number: NCT00736749
80 Recruiting Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Conditions: Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine Sulfate
Study Type: Interventional
Phase: Phase 3
Funder Type: NIH
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Number Enrolled: 330
Gender: All
Age: up to 50 Years   (Child, Adult)
NCT Number: NCT02306161

First Page    Show previous page of results Previous Page (41-60) Studies Shown (61-80) Next Page (81-100) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.